Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
Active, not recruiting · Early phase 1 · NCT05023551
Conditions: High Grade Glioma, Glioblastoma Multiforme
At a glance
- Research payments reported, 2025
- $110,296
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 39
About the trial
- Sponsor
- Sumitomo Pharma America, Inc.
- Tested
- DSP-0390 (drug)
- Dates
- Started 2021-09-08; completion 2027-10-31
- Results posted
- Not yet
This is a study of DSP-0390 in patients with recurrent high grade glioma.
From ClinicalTrials.gov, last updated 2026-07-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sumitomo Pharma America, Inc. reported $110,296 in research payments for this study in 2025 (13 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nicholas A. Butowski, MD Neurosurgery · San Francisco, CA
- Katherine B. Peters, M.D. PH.D. Neurology · Durham, NC
- Mary R. Welch, M.D. Neurology · New York, NY
- Howard Colman, M.D. Neurology · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Utah Hospital and Clinics, UT $45,437
- The Trustees of Columbia Univ in The City of Ny $33,616
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $22,455
- Duke Cancer Institute $8,788
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.